Skip to main content
logo
Maze Therapeutics, Inc. (MAZE)
NASDAQ: MAZE · Real-Time Price · USD
27.33
+0.41 (1.52%)
At close: Aug 3, 2026, 4:00 PM EDT
28.17
+0.84 (3.07%)
Pre-market: Aug 4, 2026, 4:07 AM EDT

Maze Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22
Revenue
--167.5--
Revenue Growth
-----
Gross Profit
--167.5--
Selling, General & Admin
39.0434.4526.4224.6122.83
Research & Development
115.02108.4583.573.9588.19
Total Operating Expenses
154.05142.9109.9198.55111.03
Operating Income
-134.05-142.957.59-98.55-111.03
Interest Income
12.3811.784.651.972.03
Interest Expense
-0.87----
Other Non-Operating Income (Expense)
---8.84-3.83-5.94
Total Non-Operating Income (Expense)
11.5111.78-4.18-1.86-3.91
Pretax Income
-122.54-131.1253.4-100.42-114.94
Provision for Income Taxes
--1.17--
Net Income
-122.54-131.1252.23-100.42-114.94
Net Income to Common
-122.54-131.123.41-100.42-114.94
Net Income Growth
-----
Shares Outstanding (Basic)
4943222
Shares Outstanding (Diluted)
4943322
Shares Change
420.95%1474.04%19.33%13.88%-
EPS (Basic)
-2.53-3.051.42-43.89-57.21
EPS (Diluted)
-2.53-3.051.25-43.89-57.21
EPS Growth
-----

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22
Free Cash Flow
-39.7-112.7374.81-87.27-101.17
Free Cash Flow Growth
-----
Free Cash Flow Per Share
-0.81-2.6227.40-38.14-50.36
Gross Margin
--100.00%--
Operating Margin
--34.38%--
Profit Margin
--31.18%--
FCF Margin
--44.66%--
EBITDA
-131.89-140.560.88-94.46-107.21
EBITDA Margin
--36.35%--
EBIT
-134.05-142.957.59-98.55-111.03
EBIT Margin
--34.38%--
Effective Tax Rate
-0.00%2.19%0.00%0.00%
SEC Filings: 10-K · 10-Q